ContraVir Pharmaceuticals merges with Ciclofilin Pharmaceuticals, acquiring CPI-431-32 for hepatitis B

ContraVir Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has completed its previously announced merger with Ciclofilin Pharmaceuticals, Inc., acquiring all of its outstanding equity interests. Ciclofilin's lead asset is CPI-431-32, which is in development against hepatitis B virus (HBV). CPI-431-32 strengthens ContraVir's HBV portfolio, which also contains CMX157, a highly potent HBV antiviral that works through a complementary mechanism. CPI-431-32 is positioned to be the leading non-immunosuppressive cyclophilin inhibitor antiviral for the treatment of hepatitis B and has the potential to someday be used in combination with CMX157, an additional hepatitis B candidate in Phase 1b/2a development.